AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17681993 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments for smoking cessation (specific treatments not detailed)
Number of subjects: 0
Study 17681993 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance-predictive covariates used to model probability of membership in principal strata
Number of subjects: 0
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic Awareness, Picture Vocabulary, Rapid Naming, Single Word Reading
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonemic Awareness, Picture Vocabulary, Rapid Naming (excluding Single Word Reading)
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicting which students would be in the bottom 15% and 30% of actual first grade WJBR
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicting the bottom 15% and 30% of actual third grade WJBR outcomes
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicting the bottom 15% and 30% of actual eighth grade WJBR scores
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: New tests of the same four predictor domains administered to N=500 late kindergartners through third graders
Number of subjects: 220
Study 17849193 — intervention group
Group type: EXPERIMENTAL
Intervention: Using the same regression weights from Study 1
Number of subjects: 220
Study 12448933 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 62
Study 12448933 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 62
Study 10410494 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 10410494 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 10410494 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10410494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8542861 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine mixed with lignocaine (2 mg mL‐1)
Number of subjects: 66
Study 8542861 — intervention group
Group type: EXPERIMENTAL
Intervention: diluted nalbuphine (2 mg mL‐1)
Number of subjects: 66
Study 8542861 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 66
Study 1930343 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (7.5 mg)
Number of subjects: 0
Study 1930343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6885176 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 120 ml
Number of subjects: 40
Study 6885176 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (1 g in 0.9% NaCl) infused in 250 ml
Number of subjects: 40
Study 6885176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infused in 120 ml
Number of subjects: 40
Study 6885176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl) infused in 250 ml
Number of subjects: 40
Study 30738409 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial oxygenation at 150 mm Hg
Number of subjects: 0
Study 30738409 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial oxygenation at 200 mm Hg
Number of subjects: 0
Study 30091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) with resistance training
Number of subjects: 58
Study 30091666 — intervention group
Group type: COMPARATOR
Intervention: Placebo with resistance training
Number of subjects: 58
Study 30091666 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day) without resistance training
Number of subjects: 58
Study 26608714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralyzed faces (smiling)
Number of subjects: 60
Study 26608714 — intervention group
Group type: EXPERIMENTAL
Intervention: Paralyzed faces (in repose)
Number of subjects: 60
Study 26608714 — intervention group
Group type: COMPARATOR
Intervention: Normal faces (smiling and in repose)
Number of subjects: 60
Study 24176066 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation (AF) after PCI
Number of subjects: 3681
Study 22395762 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent psychological intervention (milieu therapy interventions and music therapy) for 6 months
Number of subjects: 49
Study 22395762 — intervention group
Group type: COMPARATOR
Intervention: Standard occupational therapy
Number of subjects: 49
Study 19103988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein bypass surgery
Number of subjects: 1404
Study 16740522 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 400
Study 16740522 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 400
Study 16740522 — intervention group
Group type: EXPERIMENTAL
Intervention: Video and counseling intervention
Number of subjects: 400
Study 16740522 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 16283867 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human platelet-derived growth factor (rhPDGF)
Number of subjects: 24998
Study 12197594 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering reperfusate PO2 (PO2=200‐250 mmHg)
Number of subjects: 30
Study 12197594 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxic reperfusion (PO2=450‐550 mmHg)
Number of subjects: 30
Study 12197594 — intervention group
Group type: COMPARATOR
Intervention: Hyperoxic reperfusion with diltiazem (0.5 microg/kg)
Number of subjects: 30
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg/day
Number of subjects: 78
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1.2 mg/day
Number of subjects: 78
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 2.4 mg/day
Number of subjects: 78
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3.2 mg/day
Number of subjects: 78
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 10 mg/day
Number of subjects: 78
Study 9793313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg/day
Number of subjects: 78
Study 7906300 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant gp160 (rgp160)
Number of subjects: 40
Study 7906300 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of zidovudine for 2 weeks after each immunization
Number of subjects: 40
Study 2777592 — intervention group
Group type: EXPERIMENTAL
Intervention: Betadine‐R solution
Number of subjects: 540
Study 2777592 — intervention group
Group type: COMPARATOR
Intervention: NaCl
Number of subjects: 540
Study 1206393 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan (1.5 g or 8 g daily for 30 days)
Number of subjects: 12
Study 1206393 — intervention group
Group type: COMPARATOR
Intervention: Placebo (30-day period after treatment)
Number of subjects: 12
Study 31165653 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise and nutrition counseling plus the MORE intervention
Number of subjects: 51
Study 31165653 — intervention group
Group type: COMPARATOR
Intervention: exercise and nutrition counseling
Number of subjects: 51
Study 27890885 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration Timing Simplification Protocol (ATSP)
Number of subjects: 210
Study 25056158 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitor ECG recording
Number of subjects: 1036
Study 23263204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with fentanyl (Group I)
Number of subjects: 90
Study 23263204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anaesthesia with remifentanil (Group II)
Number of subjects: 90
Study 23263204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia (TIVA) with propofol and remifentanil (Group III)
Number of subjects: 90
Study 21781314 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 199
Study 21781314 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 199
Study 19243712 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN)
Number of subjects: 1613
Study 19243712 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT) combination
Number of subjects: 1613
Study 16677158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole infusion (80 mg intravenous bolus followed by an infusion at a rate of 8 mg per hour for 72 hours)
Number of subjects: 203
Study 16677158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 16677158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole infusion
Number of subjects: 203
Study 15290416 — intervention group
Group type: COMPARATOR
Intervention: 0% N(2)O (N0 group)
Number of subjects: 60
Study 15290416 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N(2)O (N50 group)
Number of subjects: 60
Study 15290416 — intervention group
Group type: EXPERIMENTAL
Intervention: 66% N(2)O (N66 group)
Number of subjects: 60
Study 15290416 — intervention group
Group type: EXPERIMENTAL
Intervention: Latency of MEP
Number of subjects: 60
Study 16036266 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based counseling
Number of subjects: 1329
Study 16036266 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 1329
Study 10341332 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV‐C/HGV RNA detection by PCR
Number of subjects: 100
Study 10341332 — intervention group
Group type: EXPERIMENTAL
Intervention: HGV antibodies detection by serological assay
Number of subjects: 100
Study 10341332 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with GBV‐C/HGV virus
Number of subjects: 100
Study 7574743 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI chemotherapy with 5-FU 500 mg/day for 6 weeks
Number of subjects: 19
Study 7574743 — intervention group
Group type: COMPARATOR
Intervention: Control group (no regional chemotherapy)
Number of subjects: 19
Study 1973865 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10-mg tablets
Number of subjects: 44
Study 1973865 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 44
Study 6157338 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine-decongestant combination (azatadine maleate and pseudoephedrine sulfate)
Number of subjects: 2
Study 6157338 — intervention group
Group type: COMPARATOR
Intervention: Single components (azatadine maleate or pseudoephedrine sulfate)
Number of subjects: 2
Study 6157338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 31863339 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer presence (two same-sex peers)
Number of subjects: 327
Study 31863339 — intervention group
Group type: COMPARATOR
Intervention: Alone (no peer presence)
Number of subjects: 327
Study 31863339 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance on the stoplight game
Number of subjects: 327
Study 30685679 — intervention group
Group type: EXPERIMENTAL
Intervention: SurVeil drug-coated balloon (DCB)
Number of subjects: 446
Study 30685679 — intervention group
Group type: COMPARATOR
Intervention: IN.PACT Admiral drug-coated balloon (DCB)
Number of subjects: 446
Study 28744898 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum with three different degrees of softness
Number of subjects: 20
Study 28744898 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressing extremely soft gum
Number of subjects: 20
Study 28744898 — intervention group
Group type: COMPARATOR
Intervention: Resting
Number of subjects: 20
Study 26614406 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 0
Study 26614406 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25149549 — intervention group
Group type: EXPERIMENTAL
Intervention: MUM1 positivity (cutoff value of 0.80%)
Number of subjects: 572
Study 25149549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki‐67 positivity (cutoff value of 10.25%)
Number of subjects: 572
Study 25149549 — intervention group
Group type: EXPERIMENTAL
Intervention: MUM1 positivity in FL2000 cohort
Number of subjects: 572
Study 25149549 — intervention group
Group type: EXPERIMENTAL
Intervention: MUM1 positivity in multivariate Cox regression model for FL2000 cohort
Number of subjects: 572
Study 21399488 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin, and continuous infusion of 5‐fluorouracil (ECF)
Number of subjects: 85
Study 21399488 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, cisplatin, and capecitabine (ECX)
Number of subjects: 85
Study 19417195 — intervention group
Group type: EXPERIMENTAL
Intervention: VT/VF any time
Number of subjects: 5745
Study 19417195 — intervention group
Group type: EXPERIMENTAL
Intervention: Early VT/VF (before the end of cardiac catheterization)
Number of subjects: 5745
Study 19417195 — intervention group
Group type: EXPERIMENTAL
Intervention: Late VT/VF (after the end of cardiac catheterization)
Number of subjects: 5745
Study 19417195 — intervention group
Group type: COMPARATOR
Intervention: No VT/VF
Number of subjects: 5745
Study 17244772 — intervention group
Group type: EXPERIMENTAL
Intervention: Maribavir 400 mg
Number of subjects: 31
Study 15642685 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose oral vitamin K
Number of subjects: 30
Study 15642685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11997407 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 641
Study 11997407 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 641
Study 11997407 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 641
Study 11997407 — intervention group
Group type: EXPERIMENTAL
Intervention: Total power, HF, LF, and VLF
Number of subjects: 641
Study 11997407 — intervention group
Group type: EXPERIMENTAL
Intervention: LF:HF ratios and catecholamines
Number of subjects: 641
Study 11997407 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effects on HRV
Number of subjects: 641
Study 9931787 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-excision to lobectomy
Number of subjects: 1143
Study 9931787 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive nerve mobilization
Number of subjects: 1143
Study 9931787 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-identification of the nerve
Number of subjects: 1143
Study 7712526 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine phosphate (CP) 18 g administered intravenously for 3 days
Number of subjects: 50
Study 7712526 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CP)
Number of subjects: 50
Study 2655543 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (18 + 18 mg)
Number of subjects: 6
Study 2655543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (15 + 15 mg)
Number of subjects: 6
Study 2655543 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone disodium phosphate (1.5 + 1.5 mg)
Number of subjects: 6
Study 31493952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion (1 mg lidocaine/kg bolus followed by 180 mg lidocaine/hour for 7 days)
Number of subjects: 19
Study 31493952 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study 30816665 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic kidney disease (DKD) patients
Number of subjects: 60
Study 26966012 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 40
Study 26966012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25425259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental fatigue (induced by 90 min of the computer‐based Continuous Performance Task AX version)
Number of subjects: 12
Study 25425259 — intervention group
Group type: COMPARATOR
Intervention: Control (90 min of watching emotionally neutral documentaries)
Number of subjects: 12
Study 24476474 — intervention group
Group type: EXPERIMENTAL
Intervention: EAA (essential amino acids with leucine)
Number of subjects: 8
Study 24476474 — intervention group
Group type: COMPARATOR
Intervention: EAA‐Leu (essential amino acids without leucine)
Number of subjects: 8
Study 21948229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Study Form (ESF)
Number of subjects: 317
Study 21948229 — intervention group
Group type: COMPARATOR
Intervention: Generic Study Form (GSF)
Number of subjects: 317
Study 21948229 — intervention group
Group type: COMPARATOR
Intervention: Standard Form
Number of subjects: 317
Study 19243324 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia delivery system (CLADS)
Number of subjects: 44
Study 19243324 — intervention group
Group type: COMPARATOR
Intervention: Manual control of propofol delivery
Number of subjects: 44
Study 17530108 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with meperidine (Group M)
Number of subjects: 67
Study 17530108 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine with fentanyl (Group F)
Number of subjects: 67
Study 15450787 — intervention group
Group type: EXPERIMENTAL
Intervention: High-activity allele loading of catechol-O-methyltransferase genotype
Number of subjects: 543
Study 15450787 — intervention group
Group type: COMPARATOR
Intervention: Catechol-O-methyltransferase valine158 methionine genotypes
Number of subjects: 543
Study 11589975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisporin
Number of subjects: 100
Study 11589975 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 100
Study 9713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 68
Study 9713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 68
Study 9713782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 68
Study 7977713 — intervention group
Group type: EXPERIMENTAL
Intervention: ouabain (0.5 mg i.v. 42 and 18 h before study)
Number of subjects: 10
Study 7977713 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2732784 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin (300 mg twice a day)
Number of subjects: 19
Study 2732784 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160 mg trimethoprim and 800 mg sulfamethoxazole twice a day)
Number of subjects: 19
Study 1096800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin
Number of subjects: 154
Study 1096800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (susceptible organisms)
Number of subjects: 154
Study 1096800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin (resistant organisms)
Number of subjects: 154
Study 31819947 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention provision
Number of subjects: 32
Study 31819947 — intervention group
Group type: COMPARATOR
Intervention: Control condition (reading a goal intention)
Number of subjects: 32
Study 30942012 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid massage at Shuidao (ST 28)
Number of subjects: 200
Study 27566723 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole (3.6mg mean dose at last visit)
Number of subjects: 524
Study 27566723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study 26130740 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 912
Study 26130740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 912
Study 23623280 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus cetuximab (400 mg/m² on day 1 followed by 250 mg/m² weekly)
Number of subjects: 258
Study 23623280 — intervention group
Group type: COMPARATOR
Intervention: CRT only (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² twice daily for four cycles)
Number of subjects: 258
Study 23623280 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus cetuximab
Number of subjects: 258
Study 23623280 — intervention group
Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 258
Study 21502556 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 102
Study 21502556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 18802999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (30 mg/8 hp. o)
Number of subjects: 20
Study 18802999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16274912 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital-CranioCorpoGraphy (dCCG)
Number of subjects: 33
Study 11912281 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 24
Study 11912281 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel (two doses of 0.375 mg each, 12 hours apart)
Number of subjects: 24
Study 11912281 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 10099942 — intervention group
Group type: COMPARATOR
Intervention: Iron alone
Number of subjects: 216
Study 10099942 — intervention group
Group type: COMPARATOR
Intervention: Iron and vitamin A
Number of subjects: 216
Study 10099942 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron, vitamin A and zinc
Number of subjects: 216
Study 7570929 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced whole blood
Number of subjects: 197
Study 7570929 — intervention group
Group type: COMPARATOR
Intervention: Unfiltered whole blood
Number of subjects: 197
Study 7570929 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 197
Study 2189448 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring with fentanyl 25 to 50 micrograms/kg
Number of subjects: 32
Study 2189448 — intervention group
Group type: COMPARATOR
Intervention: No EEG monitoring with fentanyl 50 micrograms/kg
Number of subjects: 32
Study 2189448 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 32
Study 2189448 — intervention group
Group type: COMPARATOR
Intervention: No EEG monitoring
Number of subjects: 32
Study 2189448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 271593 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-tufted brush
Number of subjects: 20